Top Banner
Trastuzumab Herceptin Presented by: Fatima Batool (04) Noor-ul-Huda (27)
19
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Herceptin

TrastuzumabHerceptin

Presented by:

Fatima Batool (04)

Noor-ul-Huda (27)

Page 2: Herceptin

Trastuzumab

US brand name: Herceptin

FDA approved : Yes

Page 3: Herceptin

• A recombinant humanized

monoclonal antibody

• against human epidermal

growth receptor 2 protein

(HER2)

Page 4: Herceptin

Use

• Approved to be used alone or with

other drugs to treat:

• Adenocarcinoma of stomach or gastro

esophageal junction.

• used for HER2 positive(HER2+) disease that

has metastasized (spread to other parts of the

body) in patients who have not already been

treated for metastatic cancer.

• Breast cancer that is HER2+.

Page 5: Herceptin

• HER2 overexpressed by many adenocarcinomas,

particularly breast adenocarcinomas

• Overexpression of the HER2 protein, amplification

of the HER2 gene, or both, occur in approximately

15-25% of breast cancers

• associated with aggressive behaviour in the

tumour

Page 6: Herceptin

• for women with breast cancer who have

an overexpression of HER2

• herceptin might be useful as adjuvant

therapy (before/after/in combination) with

established other chemotherapeutic

agents

• (eg anthracyclines and taxanes), surgery

and radiation treatment.

Page 7: Herceptin

• has survival benefit when given with

chemotherapy to patients

• with early, operable, and metastatic breast

cancer that has HER2 overexpression or

amplification

Page 8: Herceptin

Mode of action

• After binding to HER2 on the tumor cell

surface, trastuzumab induces an antibody-

dependent cell-mediated cytotoxicity

against tumor cells that overexpress HER2

Page 9: Herceptin

Trastuzumab mediates ADCCOnce bound to the Fc domain of trastuzumab, the NK cells release substances…

that perforate the tumour cell membrane and promote cell death

Page 10: Herceptin

Epidemiological studies assessing

Herceptin effectiveness

Page 11: Herceptin

Fig 3: Journal of the New Zealand Medical

Association, 02-June-2006, Vol 119 No 1235

Page 12: Herceptin

Side effects

• diarrhea

• constipation

• heartburn

• loss of appetite

• back, bone, joint, or muscle pain

• difficulty falling asleep or staying asleep

• numbness, burning, or tingling in the arms,

hands, feet, or legs

• changes in the appearance of nails

Page 13: Herceptin

Serious side effects

• Cardiac failure

• sore throat, fever, chills, difficulty

urinating, pain when urinating, and

other signs of infection

• nosebleeds and other unusual

bruising or bleeding

• excessive tiredness

• pale skin

Page 14: Herceptin
Page 15: Herceptin
Page 16: Herceptin
Page 17: Herceptin
Page 18: Herceptin
Page 19: Herceptin